Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Loratadine→

Loratadine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
79794-75-5
Molecular formula
C22H23ClN2O2
Molecular weight
382.9 g/mol
Drug class
Second-generation, peripherally selective histamine H1-receptor antagonistantihistamine
Mechanism of action
Selectively antagonises peripheral histamine H1 receptors, reducing histamine-mediated vasodilation, capillary permeability, bronchial smooth-muscle effects and sensory-nerve stimulation. Limited penetration into the central nervous system accounts for its low sedative effect.
Indications / reported uses
  • Relief of symptoms of allergic rhinitis, including sneezing, rhinorrhoea and nasal or ocular itching.
  • Relief of symptoms of chronic idiopathic urticaria, including pruritus and wheals.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/loratadine · https://ipc.gov.in/mandates/indian-pharmacopoeia/monographs/monographs-under-preparation/8-category-en/519-loratadine-30-01-2018.html · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Loratadine Environmental Risk Assessment (ERA) (the Loratadine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.